This webinar took place on March 29, 2024

Webinar Recording

Webinar Slides

Long COVID refers to persistent symptoms that can linger for weeks or months after an initial COVID-19 infection, even affecting individuals who may have had only mild or asymptomatic cases. This presentation sheds light on the newest insights and research into Long COVID at the University of Washington. It gives a broad overview of several ongoing studies and clinical trials run by Dr. Chu's group and covers recent findings from this work.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

• Describe specific research projects and studies conducted by the University of Washington related to Long COVID.
• Illustrate the role of University of Washington in advancing the understanding of Long COVID, including key findings and contributions to the field.
• Describe ongoing efforts and future directions in Long COVID research, including future potential improved diagnostics and therapies.

Target Audience
This activity is designed to educate commission members, practitioners, medical regulatory staff, and the public.

Speaker Biography - Helen Chu, MD, MPH

Dr. Chu is a Professor of Medicine at the University of Washington. She earned her M.D. at Duke and her M.P.H. at the UW. Dr. Chu’s research focuses on preventive interventions against influenza, RSV and emerging respiratory viruses, including SARS-CoV-2. She conducts clinical-translational research on large-scale community-based studies of respiratory viruses, with a focus on vaccines, antivirals, and diagnostics and was a Multiple Principal Investigator of the Seattle Flu Study, which first identified COVID-19 community transmission in the United States. She is also interested in defining clinical and immune correlates of protection against respiratory viruses and describing mechanisms of maternal-fetal immunity against respiratory viruses.  

Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Federation of State Medical Boards, the Washington Medical Commission, and the Washington State Department of Health. The Federation of State Medical Boards is accredited by the ACCME to provide continuing medical education for physicians. The Federation of State Medical Boards designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation Statement

The Federation of State Medical Boards designates this internet enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Director

Pamela Kohlmeier MD, JD, FACEP
Washington Medical Commission

Commercial Support

This learning activity is not funded by any commercial entity.

Disclosure Declaration

As an organization accredited by the ACCME, the Federation of State Medical Boards (FSMB) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. All faculty, planners, and others in a position to control continuing medical education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Faculty (authors, presenters, speakers and planners) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

Faculty members are asked to disclose all financial relationships they have had in the past 24 months with ineligible companies regardless of the potential relevance of each relationship to the education and of the amount. The FSMB has implemented a mechanism to identify and resolve all  conflicts of interest prior to the activity. The intent of this policy is to identify potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. The speakers, course director, and planners at the Federation of State Medical Boards, have nothing to disclose

Disclosure of Unlabeled Uses

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

Faculty and Staff Disclosures

No speaker or persons in control of content reported intent to reference unlabeled/unapproved uses of drugs or products.